Inhibition of xenograft growth by GRN163 telomerase template antagonist is equivalent to doxorubicin chemotherapy
Agent . | Dose . | Average tumor diameter (mm ± SE) . | Average TV (mm3 ± SE) . | P . | No. animals treated . |
|---|---|---|---|---|---|
| PBS | — | 11.4 ± 0.4 | 794 ± 89 | — | 16 |
| GRN163 | 10 nmol, 5 ×/wk | 9.5 ± 0.2 | 461 ± 38 | ≤ .002 | 14 |
| Doxorubicin | 3 mg/kg, 6 doses | 9.7 ± 0.4 | 487 ± 57 | ≤ .008 | 8 |
Agent . | Dose . | Average tumor diameter (mm ± SE) . | Average TV (mm3 ± SE) . | P . | No. animals treated . |
|---|---|---|---|---|---|
| PBS | — | 11.4 ± 0.4 | 794 ± 89 | — | 16 |
| GRN163 | 10 nmol, 5 ×/wk | 9.5 ± 0.2 | 461 ± 38 | ≤ .002 | 14 |
| Doxorubicin | 3 mg/kg, 6 doses | 9.7 ± 0.4 | 487 ± 57 | ≤ .008 | 8 |
NOD/SCID mice were sublethally irradiated and inoculated with 10 × 106 CAG myeloma cells by way of a subcutaneous route. When tumor volumes approached 100 mm3, mice were divided into 3 groups of 4 to 5 mice per group. Animals were treated with PBS or GRN163 (10 nmol) injected locally 5 days per week for 3 weeks or with doxorubicin (3 mg/kg) injected through an intraperitoneal route twice a week for 3 weeks. Tumors were measured by calipers, and tumor volume was calculated using the formula mm3 = 4/3 πr3, where r = (1 + w)/4. Shown are tumor measurements on day 21 of treatment. P values are for TV PBS versus treatment.
—indicates not applicable.